Please find the newest company article here: Articles of Association–23 March 2020.pdf
BioPorto is subject to the recommendations prepared by the Committee on Corporate Governance, which are available at www.corporategovernance.dk.
The Board of Directors regularly assesses how the recommendations may contribute to strengthening the management of BioPorto and ensure maximum value creation for the company’s shareholders. Once a year, the Board of Directors reviews the recommendations, evaluating BioPorto’s degree of compliance. The Board of Directors believes that BioPorto complies with all of the recommendations of the Committee.
The Statutory report on Corporate Governance is attached below.
The Statutory reports on Corporate Governance 2012 – 2018:
CORPORATE SOCIAL RESPONSIBILITY
BioPorto is aware of its corporate social responsibility and endeavors to improve social and environmental conditions. In addition the corporate social responsibility report is provided in BioPorto’s Annual Report. BioPorto has signed the UN Global Compact, and the latest Communication on Progress, which is available here.
BioPorto Diversity Policy – see more here.
REMUNERATION POLICY AND GUIDELINES FOR INCENTIVE-BASED REMUNERATION
Remuneration policy and guidelines for incentive-based remuneration of the board of directors and executive management of BioPorto A/S.
These Guidelines have been prepared pursuant to the Recommendations on Corporate Governance, Recommendation 4 and section 139 of the Danish Companies Act, according to which BioPorto A/S must prepare a remuneration policy and guidelines for incentive remuneration covering the Company’s Board of Directors and Executive Management, where “Executive Management” is defined as the Manager(s) registered with the Danish Business Authority as Manager(s) of the Company.
The Guidelines were approved at the Annual General Meeting of BioPorto A/S on March 18, 2019.
The guidelines are presented for the general meeting’s approval at least every four years, and upon significant changes.
Information about the current remuneration of the Company’s Board of Directors and Executive Management is found in the annual report, which is also available on the annual report section of this website.
BioPorto carries out development and sales activities in the area of diagnostics. Through its activities, the Group is exposed to a number of risks that could significantly affect its operations in the event these risks are not correctly assessed and managed. BioPorto’s policy is to identify and mitigate risks deriving from the Group’s operations and to establish adequate insurance coverage. BioPorto has established risk management as a formalised process for the purpose of generating a close connection between the Group’s ongoing objectives and activities and the individual risk elements within the Group’s sphere of activity. In connection with the new corporate strategy, Management has specifically addressed risks relating to new objectives. Follow this link to learn more: Risk Management
DATA PROTECTION POLICY
BioPorto complies with the European GDPR rules, which gives individuals a number of rights. For more information regarding use of this site, privacy, and legal/compliance policies, please refer to the following: